StockNews.com started coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Free Report) in a report published on Thursday morning. The firm issued a sell rating on the basic materials company’s stock.
Separately, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Arcadia Biosciences in a research note on Wednesday, August 21st.
Arcadia Biosciences Stock Down 0.7 %
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.27 by ($0.49). Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. The business had revenue of $1.31 million for the quarter, compared to analyst estimates of $0.95 million. During the same quarter in the prior year, the firm posted ($2.64) earnings per share. As a group, equities analysts anticipate that Arcadia Biosciences will post -1.7 EPS for the current year.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Featured Stories
- Five stocks we like better than Arcadia Biosciences
- Technology Stocks Explained: Here’s What to Know About Tech
- California Resources Stock Could Be a Huge Long-Term Winner
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.